SCHEMBL29535106

SCHEMBL29535106

Cc1c[nH]c2ccncc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.52
HTR6 P50406 2/20 0.51
PIM1 P11309 3/20 0.47
PIM3 Q86V86 1/20 0.47
PIM2 Q9P1W9 1/20 0.47
ACHE P22303 4/20 0.46
TDO2 P48775 1/20 0.44
DYRK1A Q13627 5/20 0.43
GSK3B P49841 4/20 0.43
NFATC1 O95644 3/20 0.43
CDK2 P24941 1/20 0.41
DYRK1B Q9Y463 1/20 0.41
IMPDH2 P12268 1/20 0.39
MAPK1 P28482 1/20 0.39
HSD17B10 Q99714 1/20 0.39
HASPIN Q8TF76 2/20 0.39
CCNT1 O60563 1/20 0.39
CDK9 P50750 1/20 0.39
GPR84 Q9NQS5 1/20 0.38
KDR P35968 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3224448 1.00 ATM (0.52) ATMHTR6PIM1PIM3PIM2
SCHEMBL2619228 0.83 DYRK1A (0.56) ATMHTR6PIM1PIM3PIM2
SCHEMBL31692009 0.80 ATM (0.48) ATMHTR6PIM1PIM3PIM2
SCHEMBL30067091 0.75 HASPIN (0.59) HTR6PIM1ACHETDO2DYRK1A
SCHEMBL14059758 0.75 GSK3B (0.51) HTR6PIM1ACHETDO2DYRK1A
SCHEMBL30295197 0.75 PIM1 (0.59) HTR6PIM1ACHETDO2DYRK1A
SCHEMBL2050489 0.75 HASPIN (0.59) HTR6PIM1ACHETDO2DYRK1A
SCHEMBL10587 0.75 PIM1 (0.59) HTR6PIM1ACHETDO2DYRK1A
SCHEMBL16168495 0.75 HTR6 (0.56) HTR6PIM1ACHEDYRK1AGSK3B
SCHEMBL24556549 0.75 KDM4C (0.47) PIM1PIM3PIM2DYRK1AGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304577-A1 TYK2 INHIBITORS BIOGEN MA INC. 2025-10-02 US disclosed
EP-4225742-A1 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES Enliven Therapeutics, Inc. (US) 2023-08-16 EP disclosed
WO-2022076975-A1 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ENLIVEN THERAPEUTICS, INC. (US) 2022-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304577-A1 TYK2 INHIBITORS TYK2, JAK2, JAK1 ATM 407/4885HTR6 2272/4885PIM1 248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.